文献速递胸部肿瘤

局限期小细胞肺癌等待重大变革:目前仍是更多相同方案

Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same.
PubMed 文献 · J Clin Oncol · 2023-02-23

本文为肿瘤学大查房系列综述,围绕局限期小细胞肺癌(SCLC)放化疗方案展开。同步放化疗仍是局限期SCLC的核心治疗,每日两次放疗为标准方案之一;CALGB 30610/RTOG 0538和CONVERT研究显示每日一次与每日两次放疗生存相似,但每日一次放疗未显示优效,试验设计限制其非劣效结论。

要点

  • 同步放化疗仍是局限期SCLC的核心治疗。
  • 每日两次放疗是局限期SCLC原发根治性治疗中少数采用每日两次方案的瘤种之一。
  • CALGB 30610/RTOG 0538和CONVERT显示每日一次与每日两次放疗生存相似,但每日一次放疗未显示优效。

核心结论

  • 同步化疗联合每日两次放疗仍是局限期SCLC的标准治疗。
  • 每日一次剂量递增放疗未显示优于每日两次放疗,且试验设计限制其非劣效结论。

研究设计与样本

  • 本文为肿瘤学大查房系列综述,结合病例展示、诊疗挑战、相关文献回顾及作者建议的管理方法。
  • 回顾了Intergroup 0096、CALGB 30610/RTOG 0538和CONVERT等研究。

主要发现

  • Intergroup 0096显示每日两次放疗优于每日一次放疗,但每日一次放疗组放疗剂量较低。
  • CALGB 30610/RTOG 0538和CONVERT显示每日一次与每日两次放疗生存相似。
  • 每日一次放疗未显示优于每日两次放疗,试验设计限制将剂量递增每日一次放疗判定为非劣效于每日两次放疗。

关键数值与推荐

  • 同步放化疗为局限期SCLC的核心治疗。
  • 每日两次放疗为局限期SCLC原发根治性治疗的标准方案之一。

临床怎么用

  • 同步化疗联合每日两次放疗仍是局限期SCLC的标准治疗。

局限性

  • Intergroup 0096中每日一次放疗组放疗剂量较低。
  • CALGB 30610/RTOG 0538和CONVERT的试验设计限制将剂量递增每日一次放疗判定为非劣效于每日两次放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Concurrent chemoradiotherapy remains central to the treatment of limited-stage small-cell lung cancer (SCLC). SCLC is one of the few tumors treated with twice-daily radiotherapy (RT) in the primary definitive setting, a regimen that was established when Intergroup 0096 demonstrated its superiority over once-daily RT. However, questions remained about the optimal chemoradiotherapy regimen given the low RT dose used in the once-daily RT arm of Intergroup 0096. CALGB 30610/RTOG 0538 and CONVERT attempted to establish whether dose-escalated once-daily RT was superior to twice-daily RT in limited-stage SCLC. Although both studies showed similar survival between treatment regimens, once-daily RT was not found to be superior to twice-daily RT, and trial design limited the ability to conclude dose-escalated once-daily RT as noninferior to twice-daily RT. Thus, twice-daily RT with concurrent chemotherapy remains a standard of care in limited-stage SCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Deek MP, Haigentz M, Jabbour SK, et al. Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same. J Clin Oncol. 2023. PMID: 36821803. doi:10.1200/JCO.22.02316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。